Helen Sabzevari Biography and Net Worth

CEO of Precigen

Dr. Helen Sabzevari is President and CEO of Precigen and member of the Precigen Board of Directors. Dr. Sabzevari brings extensive expertise in research and development of immunotherapy-based therapeutics as well as experience translating novel treatments from pre-clinical stage into the clinic. From 2015 to 2017, Dr. Sabzevari co-founded and served as Chief Scientific Officer of Compass Therapeutics, a fully-integrated drug discovery and development company focused on manipulating the immune system to treat human disease. From 2008 to 2014, Dr. Sabzevari served as Senior Vice President of Immuno-Oncology as well as Global Head of Immunotherapy, Oncology, Global Research and Early Development at EMD Serono (a subsidiary of Merck KGaA, Darmstadt, Germany). During her tenure, she led the immuno-oncology discovery and early development translational innovation platform and brought forward numerous pre-clinical and clinical assets including avelumab, an approved anti-programmed death ligand-1 (PD-L1) checkpoint inhibitor. From 1998 to 2008, Dr. Sabzevari led the Molecular Immunology Group at the Laboratory of Tumor Immunology and Biology at the US National Cancer Institute (LTIB-NCI), where she was focused on design, development and delivery of novel vaccines and immunotherapies for a range of human cancers. Dr. Sabzevari’s contributions in the field of tumor immunology earned her the National Institutes of Health (NIH) merit award for major contribution to the field of cancer immunotherapy, and she has also received the Mass High Tech’s Women to Watch Award and the PharmaVOICE 100 Award. Most recently, Dr. Sabzevari received the Society for Immunotherapy of Cancer (SITC) Team Science Award for her work on the NCI Cancer Immunotherapy Program Team. Dr. Sabzevari received her doctorate degree in cell and molecular immunology and completed her postdoctoral work at the department of immunology at the Scripps Research Institute working on various immunotherapeutic modalities in the treatment of cancer and autoimmune diseases.

What is Helen Sabzevari's net worth?: The estimated net worth of Helen Sabzevari is at least $1.28 million as of August 25th, 2023. Dr. Sabzevari owns 1,560,004 shares of Precigen stock worth more than $1,284,195 as of November 5th. This net worth approximation does not reflect any other assets that Dr. Sabzevari may own. Additionally, Dr. Sabzevari receives a salary of $1,020,000.00 as CEO at Precigen. Learn More about Helen Sabzevari's net worth.
How old is Helen Sabzevari?: Dr. Sabzevari is currently 62 years old. There are 6 older executives and no younger executives at Precigen. Learn More on Helen Sabzevari's age.
What is Helen Sabzevari's salary?: As the CEO of Precigen, Inc., Dr. Sabzevari earns $1,020,000.00 per year. Learn More on Helen Sabzevari's salary.
How do I contact Helen Sabzevari?: The corporate mailing address for Dr. Sabzevari and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on Helen Sabzevari's contact information.
Has Helen Sabzevari been buying or selling shares of Precigen?: Helen Sabzevari has not been actively trading shares of Precigen in the last ninety days. Most recently, Helen Sabzevari sold 76,969 shares of the business's stock in a transaction on Friday, August 25th. The shares were sold at an average price of $1.53, for a transaction totalling $117,762.57. Following the completion of the sale, the chief executive officer now directly owns 1,560,004 shares of the company's stock, valued at $2,386,806.12. Learn More on Helen Sabzevari's trading history.
Who are Precigen's active insiders?: Precigen's insider roster includes Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.
Are insiders buying or selling shares of Precigen?: In the last year, Precigen insiders bought shares 2 times. They purchased a total of 155,509 shares worth more than $186,326.81. The most recent insider tranaction occured on August, 9th when SVP Jeffrey Thomas Perez bought 58,823 shares worth more than $49,999.55. Insiders at Precigen own 44.9% of the company. Learn More about insider trades at Precigen.
Information on this page was last updated on 8/9/2024.

Helen Sabzevari Insider Trading History at Precigen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/25/2023	Sell	76,969	$1.53	$117,762.57	1,560,004
8/18/2023	Sell	55,855	$1.66	$92,719.30	1,495,386
8/11/2023	Sell	41,436	$1.44	$59,667.84	1,409,654
8/4/2023	Sell	52,870	$1.10	$58,157.00	1,309,503
1/27/2023	Buy	22,857	$1.75	$39,999.75	937,613
5/13/2022	Sell	177,968	$1.19	$211,781.92	897,091
1/5/2022	Sell	6,960	$3.59	$24,986.40
1/3/2022	Sell	3,848	$3.67	$14,122.16
7/19/2021	Sell	12,531	$5.43	$68,043.33
5/13/2021	Sell	47,433	$6.40	$303,571.20	752,490
1/5/2021	Sell	9,040	$10.56	$95,462.40	424,299
7/20/2020	Sell	12,220	$4.58	$55,967.60	414,365
1/6/2020	Sell	6,732	$5.83	$39,247.56	104,734
1/3/2020	Sell	3,886	$5.77	$22,422.22	90,953
7/18/2019	Sell	8,484	$7.47	$63,375.48	70,825
7/18/2018	Sell	8,402	$14.54	$122,165.08	25,000

Helen Sabzevari Buying and Selling Activity at Precigen

Precigen Company Overview

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Today's Range

Now: $0.82

$0.80

$0.84

50 Day Range

MA: $0.95

$0.79

$1.15

2 Week Range

Now: $0.82

$0.79

$1.93

Volume

707,590 shs

Average Volume

950,035 shs

Market Capitalization

$208.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

A new way to play the AI boom (act before November 19)

From Behind the Markets | Ad

There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as little as $16 and a brokerage account.

Click here to get the ticker >>>

Helen Sabzevari Biography and Net Worth

What is Helen Sabzevari's net worth?

How old is Helen Sabzevari?

What is Helen Sabzevari's salary?

How do I contact Helen Sabzevari?

Has Helen Sabzevari been buying or selling shares of Precigen?

Who are Precigen's active insiders?

Are insiders buying or selling shares of Precigen?